Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients

Leuk Lymphoma. 2019 Jan;60(1):222-225. doi: 10.1080/10428194.2018.1459602. Epub 2018 May 2.

Authors

Bastien Jamet¹, Clément Bailly¹, Thomas Carlier^{1

2}, Lucie Planche³, Cyrille Touzeau^{2

4}, Françoise Kraeber-Bodéré^{1

2

5}, Philippe Moreau^{2

4}, Caroline Bodet-Milin^{1

2}

Affiliations

¹ a Nuclear Medicine Unit, University Hospital , Nantes , France.
² b INSERM U892, CRCNA , Nantes , France.
³ c Statistics Unit, University Hospital , Nantes , France.
⁴ d Department of Haematology , University Hospital , Nantes , France.
⁵ e Nuclear Medicine Unit, ICO-Gauducheau , Nantes-Saint-Herblain , France.

PMID: 29717914
DOI: 10.1080/10428194.2018.1459602

No abstract available

Publication types

Evaluation Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Disease Progression
Female
Fluorodeoxyglucose F18 / administration & dosage
Follow-Up Studies
Humans
Male
Middle Aged
Multiple Myeloma / diagnostic imaging*
Multiple Myeloma / mortality
Multiple Myeloma / therapy
Neoplasm Recurrence, Local / mortality*
Neoplasm Recurrence, Local / therapy
Positron Emission Tomography Computed Tomography*
Predictive Value of Tests
Prognosis
Progression-Free Survival
Radiopharmaceuticals / administration & dosage
Stem Cell Transplantation*
Transplantation, Autologous

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18